Atara Biotherapeutics, Inc. (ATRA) financial statements (2020 and earlier)

Company profile

Business Address 611 GATEWAY BLVD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments259310166256320104
Cash and cash equivalents746179482422
Short-term investments1852498720829782
Restricted cash and investments00    
Other undisclosed current assets14126542
Total current assets:273321172261325106
Noncurrent Assets
Operating lease, right-of-use asset14
Property, plant and equipment546944300
Restricted cash and investments111   
Other noncurrent assets110000
Total noncurrent assets:707046300
TOTAL ASSETS:343392218264325106
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities231420753
Accounts payable8415310
Accrued liabilities   111
Employee-related liabilities15116431
Taxes payable     0
Debt 00   
Other liabilities663   
Other undisclosed current liabilities819425 
Total current liabilities:37402810103
Noncurrent Liabilities
Long-term debt and lease obligation1401   
Capital lease obligations01   
Operating lease, liability14
Liabilities, other than long-term debt1    0
Other liabilities1    0
Other undisclosed noncurrent liabilities 131210 
Total noncurrent liabilities:151312100
Total liabilities:52534010103
Stockholders' equity
Stockholders' equity attributable to parent291339178254315103
Common stock000000
Additional paid in capital1,109867475431414144
Accumulated other comprehensive income (loss)0(0)(0)(0)(1)(0)
Accumulated deficit(818)(527)(297)(177)(98)(41)
Total stockholders' equity:291339178254315103
TOTAL LIABILITIES AND EQUITY:343392218264325106

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:   (5)(5) 
Operating expenses(296)(237)(122)(81)(58)(28)
Other undisclosed operating income   55 
Operating loss:(296)(237)(122)(81)(58)(28)
Nonoperating income (expense)56221(1)
Investment income, nonoperating     (1)
Other nonoperating income56221 
Interest and debt expense(0)     
Loss from continuing operations before equity method investments, income taxes:(291)(231)(120)(79)(57)(29)
Other undisclosed income from continuing operations before income taxes0    1
Loss from continuing operations before income taxes:(291)(231)(120)(79)(57)(28)
Income tax expense (benefit)(0)00(0)00
Net loss available to common stockholders, diluted:(291)(231)(119)(79)(57)(28)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(291)(231)(119)(79)(57)(28)
Other comprehensive loss     (0)
Comprehensive loss:(291)(231)(119)(79)(57)(28)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(0)00(0) 
Comprehensive loss, net of tax, attributable to parent:(290)(231)(119)(79)(58)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: